{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:50:09Z","timestamp":1671537009373},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T00:00:00Z","timestamp":1433462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s11912-015-0460-2","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T14:12:05Z","timestamp":1433427125000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel Agents in Mantle Cell Lymphoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Anita","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,5]]},"reference":[{"key":"460_CR1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511\u20138.","journal-title":"J Clin Oncol"},{"key":"460_CR2","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","volume":"84","author":"F Bosch","year":"1994","unstructured":"Bosch F, Jares P, Campo E, et al. PRAD-1\/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726\u201332.","journal-title":"Blood"},{"key":"460_CR3","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416\u201323.","journal-title":"J Clin Invest"},{"key":"460_CR4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","volume":"166","author":"L Nordstrom","year":"2014","unstructured":"Nordstrom L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma\u2014a Nordic Lymphoma Group study. Br J Haematol. 2014;166:98\u2013108.","journal-title":"Br J Haematol"},{"key":"460_CR5","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","volume":"15","author":"M Bernard","year":"2001","unstructured":"Bernard M, Gressin R, Lefrere F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15:1785\u201391.","journal-title":"Leukemia"},{"key":"460_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185\u201397.","journal-title":"Cancer Cell"},{"key":"460_CR7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385\u20137.","journal-title":"Blood"},{"key":"460_CR8","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"460_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","volume":"21","author":"R Schaffel","year":"2010","unstructured":"Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21:133\u20139.","journal-title":"Ann Oncol"},{"key":"460_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29\u201338.","journal-title":"Br J Haematol"},{"key":"460_CR11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/his.12009","volume":"62","author":"N Vogt","year":"2013","unstructured":"Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology. 2013;62:334\u201342.","journal-title":"Histopathology"},{"key":"460_CR12","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:18250\u20135. This study defines genomic alterations that explain differential sensitivity to ibrutinib in MCL cell lines.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"460_CR13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119:1963\u201371.","journal-title":"Blood"},{"key":"460_CR14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"460_CR15","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","volume":"123","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123:2988\u201396.","journal-title":"Blood"},{"key":"460_CR16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semcancer.2011.09.008","volume":"21","author":"S Parekh","year":"2011","unstructured":"Parekh S, Weniger MA, Wiestner A. New molecular targets in mantle cell lymphoma. Semin Cancer Biol. 2011;21:335\u201346.","journal-title":"Semin Cancer Biol"},{"key":"460_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26\u201338.","journal-title":"Blood"},{"key":"460_CR18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:3383\u20139. Phase II study showing remarkable efficacy of the BTK-inhibitor ibrutinib and led to breakthrough FDA-approval of ibrutinib in MCL.","journal-title":"J Clin Oncol"},{"key":"460_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676\u201384.","journal-title":"J Clin Oncol"},{"key":"460_CR20","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","volume":"48","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma. 2007;48:2172\u20138. The phase II study that led to FDA-approval of lenalidomide in patients who previously received bortezomib.","journal-title":"Leuk Lymphoma"},{"key":"460_CR21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol. 2012;13:716\u201323.","journal-title":"Lancet Oncol"},{"key":"460_CR22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"460_CR23","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119:4597\u2013607.","journal-title":"Blood"},{"key":"460_CR24","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1535-7163.MCT-10-1108","volume":"10","author":"G Dasmahapatra","year":"2011","unstructured":"Dasmahapatra G, Lembersky D, Son MP, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011;10:1686\u201397.","journal-title":"Mol Cancer Ther"},{"key":"460_CR25","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398\u2013405.","journal-title":"Blood"},{"key":"460_CR26","unstructured":"Seymour JF, Gerecitano JF, Kahl BS, et al.: The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Presented at the ASH, 2013."},{"key":"460_CR27","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003\u20138.","journal-title":"Blood"},{"key":"460_CR28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/10428190801993470","volume":"49","author":"TE Witzig","year":"2008","unstructured":"Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008;49:1074\u201380.","journal-title":"Leuk Lymphoma"},{"key":"460_CR29","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:4473\u20139.","journal-title":"J Clin Oncol"},{"key":"460_CR30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442\u20139.","journal-title":"J Clin Oncol"},{"key":"460_CR31","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807\u201312. The phase II study that led to FDA-approval of bortezomib.","journal-title":"Blood"},{"key":"460_CR32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"460_CR33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88\u201395.","journal-title":"J Immunol"},{"key":"460_CR34","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867\u201374.","journal-title":"J Clin Oncol"},{"key":"460_CR35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520\u20135.","journal-title":"Ann Oncol"},{"key":"460_CR36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","volume":"52","author":"CT Kouroukis","year":"2011","unstructured":"Kouroukis CT, Fernandez LA, Crump M, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011;52:394\u20139.","journal-title":"Leuk Lymphoma"},{"key":"460_CR37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"460_CR38","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24:2892\u20137.","journal-title":"Ann Oncol"},{"key":"460_CR39","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688\u201395.","journal-title":"J Clin Oncol"},{"key":"460_CR40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","volume":"31","author":"JJ Buggy","year":"2012","unstructured":"Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31:119\u201332.","journal-title":"Int Rev Immunol"},{"key":"460_CR41","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"460_CR42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"},{"key":"460_CR43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2014","unstructured":"Fenske TS, Zhang MJ, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273\u201381.","journal-title":"J Clin Oncol"},{"key":"460_CR44","doi-asserted-by":"crossref","unstructured":"Mussetti A, Kumar A, Dahi PB, et al.: Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev, 2014","DOI":"10.1016\/j.blre.2014.10.001"},{"key":"460_CR45","doi-asserted-by":"crossref","unstructured":"Smith SM, Pitcher BN, Jung SH, et al.: Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory b cell lymphomas: alliance A051201 and A051202. Blood (ASH Annual Meeting Abstracts) 124 (21), 2014","DOI":"10.1182\/blood.V124.21.3091.3091"},{"key":"460_CR46","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","volume":"113","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Inwards DJ, Rowland Jr KM, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113:508\u201314.","journal-title":"Cancer"},{"key":"460_CR47","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822\u20139.","journal-title":"J Clin Oncol"},{"key":"460_CR48","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347\u201356.","journal-title":"J Clin Oncol"},{"key":"460_CR49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12:361\u20138.","journal-title":"Lancet Oncol"},{"key":"460_CR50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","volume":"28","author":"TS Lin","year":"2010","unstructured":"Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol. 2010;28:418\u201323.","journal-title":"J Clin Oncol"},{"key":"460_CR51","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1158\/1078-0432.CCR-14-0805","volume":"20","author":"B Holkova","year":"2014","unstructured":"Holkova B, Kmieciak M, Perkins EB, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and \u201cnonhybrid\u201d (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014;20:5652\u201362.","journal-title":"Clin Cancer Res"},{"key":"460_CR52","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Bouabdallah K, Stilgenbauer S, et al.: Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 124 (21), 2014","DOI":"10.1182\/blood.V124.21.3067.3067"},{"key":"460_CR53","doi-asserted-by":"crossref","unstructured":"Infante JR, Shapiro GI, Witteveen PO, et al.: A phase I study of the single-agent CDK4\/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol (ASCO Abstract) 32 (5s), 2014","DOI":"10.1200\/jco.2014.32.15_suppl.2528"},{"key":"460_CR54","unstructured":"Davids MS, Seymour JF, Gerecitano J, et al.: Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol (ASCO Abstract) 32:5s (suppl), 2014"},{"key":"460_CR55","doi-asserted-by":"crossref","unstructured":"Evens A, Vose J, Harb W, et al.: A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed\/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 120, 2012","DOI":"10.1182\/blood.V120.21.55.55"},{"key":"460_CR56","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912\u20139.","journal-title":"J Clin Oncol"},{"key":"460_CR57","doi-asserted-by":"crossref","unstructured":"Cheng S, Guo A, Lu P, et al.: Functional characterization of BTK mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia, 2014","DOI":"10.1038\/leu.2014.263"},{"key":"460_CR58","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286\u201394.","journal-title":"N Engl J Med"},{"key":"460_CR59","doi-asserted-by":"crossref","unstructured":"Zhao X, Bodo J, Sun D, et al.: Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2014.","DOI":"10.1111\/bjh.13149"},{"key":"460_CR60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/leu.2013.249","volume":"28","author":"M Axelrod","year":"2014","unstructured":"Axelrod M, Ou Z, Brett LK, et al. Combinatorial drug screening identifies synergistic co-targeting of Bruton\u2019s tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia. 2014;28:407\u201310.","journal-title":"Leukemia"},{"key":"460_CR61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.12206","volume":"161","author":"G Dasmahapatra","year":"2013","unstructured":"Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol. 2013;161:43\u201356.","journal-title":"Br J Haematol"},{"key":"460_CR62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrclinonc.2014.137","volume":"11","author":"AM Intlekofer","year":"2014","unstructured":"Intlekofer AM, Younes A. Precision therapy for lymphoma\u2014current state and future directions. Nat Rev Clin Oncol. 2014;11:585\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"460_CR63","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771\u20139.","journal-title":"Blood"},{"key":"460_CR64","doi-asserted-by":"crossref","unstructured":"Wang M, Hagemeister F, Westin J, et al.: ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial. Blood (ASH Annual Meeting Abstracts) 124, 2014","DOI":"10.1016\/j.clml.2015.07.131"},{"key":"460_CR65","doi-asserted-by":"crossref","unstructured":"Kahl BS, Spurgeon SE, Furman RR, et al.: Results of a phase I study of idelalisib, a PI3Kdelta inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood, 2014","DOI":"10.1182\/blood-2013-11-537555"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-015-0460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-015-0460-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-015-0460-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T01:27:47Z","timestamp":1599096467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-015-0460-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,5]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1007\/s11912-015-0460-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,5]]},"article-number":"34"}}